注射用鹽酸吉西他濱-文庫吧資料
2025-08-11 09:13本頁面
【正文】 Ⅲ Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in ChemotherapyNaive Patients With AdvancedStage Non–SmallCell Lung Cancer[J].Clin Oncol, 2022, 26(21):35433551. AB, Nemunaitis J, Denham C, et al. Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmallcell lung cancer[J].J Clin Oncol, 2022, 18(1):122130. Meerbeeck. Jan P, Hedy Lee Kindler. The role of gemcitabine in the treatment of malignant mesothelioma. [J].Seminars in Oncology, 2022, 29(1):7076. 4. Melo MJ, Barradas P, Costa A, et al. Results of a randomised phase III trial paring 4 cisplatin (P)based regimens in the treatment of locally advanced and metastatic nonsmall cell lung cancer (NSCLC): Mitomycin/cisplatin (MVP) is no longer a therapeutic option. Proc Am Soc Clin Oncol 21:302a, 2022 (abstr 1205) 含吉西他濱 方案 與紫杉醇方案 TTP的對比 研究組 方案 病例數(shù) 有效率 % 中位生存期 3/4度中性粒細(xì)胞減 少 3/4度血小板減少 Altavilla等[1] GEM 1250mg/M2 d1,8,21天重復(fù) 21 33 32周 無 % Ricci等 [2] GEM 1000mg/M2 d1,8,15， 28天重復(fù) 44 未提 未提 Martoni等 [3] GEM 1000mg/M2 d1,8,15，
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1